Agenus uses the power of the immune system to develop innovative product candidates against cancer.

Its technologies and candidates have the potential to treat cancer as well as other immune-mediated diseases. The company has assembled a broad portfolio of antibodies including checkpoint inhibitors and other checkpoint modulators, neo-antigen vaccines and adjuvants. Agenus’ strategy combines its intellectual and technical assets with its broad pipeline with the aim of bringing curative treatments to cancer patients.